top of page
About
Who are we?
We are a purpose driven company focused on finding treatments for rare diseases using proprietary Artificial Intelligence systems.
Our Mission:
Enable the emergence of treatments by showcasing the untapped academic research.
Why are we approaching rare diseases?
Over 300 million people worldwide live with a rare disease, with an estimated 70% of them starting in childhood. Despite the urgent need, developing new treatments is an uphill battle: they can cost billions of dollars, and often can take over a decade to bring to market. The rarity of these conditions, combined with the immense challenges of creating effective therapies, means that individuals with rare diseases are frequently overlooked by healthcare systems. As a result, 95% of rare diseases remain without a single approved treatment.
*
What do we provide?
We aim to collaborate with manufacturers and propose to laboratories to bring treatments to market, ensuring that innovative solutions reach the patients who need them most. Our approach focuses on biotherapies, supported by supply agreement contracts. We aim to provide a faster and more cost-effective solution for delivering drugs to patients by utilizing existing products.
How?
Our R&D is built on a proprietary AI pharma backbone called "SAVE" (Search, Accelerate, Value, and Embrace). This allows us to target a development timeline of less than 36 months.
Our SAVE Model
Search
cross-matches rare diseases with unmet medical needs and Biologics to land on new possibilities of treatments
Accelerate
integrates regulatory specifics and accelerate steps to develop dossiers and then disrupt the timing of building files before submission
Value
combines market access, forecasting to bring a value proposition
Embrace
AI continuous improvement process
Company Vision
Vision
How we see the future of the industry
5000 clinical trials are published worldwide each year, for the use of existing drugs on rare diseases. We aim to maximize the utilizations of these clinical trials and transform the way rare disease treatments are developed:
-
Maximizing the Value of Research: Every piece of academic research on rare diseases is recognized, utilized, and given the attention it deserves.
-
​Empowered by AI: Our AI-driven platform analyzes and integrates diverse research to accelerate breakthroughs in treatment.
-
Faster Development Timelines: A streamlined approach will drastically reduce the time from treatment inception to patient infusion.
In the next five years, we aim to bring 30 new treatments to patients by forging strong partnerships with pharmaceutical laboratories committed to commercializing these breakthroughs.
Our vision is a future where every rare disease has a path to treatment—leveraging untapped research, innovative technologies, and collaborations to put patients first.
Granted ODD's
FDA granted Orphan Drug Designations (ODD) for the following Indications:
2 July 2024
Bevacizumab
Recurrent Respiratory Papillomatosis (RRP)
15 July 2024
Bevacizumab
Neurofibromatosis type 2 (NF2)
26 July 2024
Infliximab
Kawasaki disease (KD - Children)
16 December 2024
Rituximab
Idiopathic Thrombocytopenic Purpura (ITP)
13 March 2025
Adalimumab
Takayasu arteritis (TA)
Our comprehensive product portfolio includes FDA-granted solutions as well as those currently undergoing the approval process
Pipeline
News
Executive Team
Dr. Marc Childs,
Chairman
-
Doctor, pharmacologist and Insead
-
>40 years in the pharmaceutical industry
-
Founder of Delbert Pharma (LBO with Sagard, Credit Agricole Bank and Vivalto)
-
Private equity investor in healthcare
-
Pierre-Alexandre Teulié,
Chief Executive Officer
-
ENA and Sciences Po and Harvard Kennedy School
-
>30 years of experience in industry
-
Deputy GM of Nestlé France
-
COS of Carrefour (Fortune 100 companies)
-
Mehdi-Alexandre Manga,
Chief Innovation Officer
-
EM Lyon, pôle Entrepreneur
-
> 8 years in tech industry and entrepreneurship
-
Founder of 3 startups (including 1 software publishing)
-
Management of the implementation of a national technologicial platform (France Relance Initiative)
-
Maryline Legouas,
Chief Marketing Officer
-
Phd Pharmacist at Angers University
-
25 years+ in Biotech & Pharmaceutical industry
-
Marketing director at Gensight
-
Marketing director at Eisai
-
Marketing and sales manager at Amgen
-
Jean-Christophe Liard,
Chief Financial Officer
-
La Sorbonne University
-
> 18 years of experience in corporate finance
-
Head of corporate finance of ABN AMRO France (pharmaceutical and healthcare coverage)
-
Equity analyst at Richelieu Finance (EUR 6bn AuM)
-
bottom of page